1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Themis Medicare Limited

Themis Medicare Limited

THEMISMED.BO
Themis Medicare LimitedIN flagBombay Stock Exchange
121.00
INR
+2.55
- -
11.19BMarket Cap
Themis Medicare Limited
THEMISMED.BO
(Bombay Stock Exchange)

Recent

price

121.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
31.31
19.59
21.55
23.08
23.84
27.3
23.75
22.72
19.89
21.82
24.96
42.54
37.43
40.92
44.04
- -
37.06
Revenue per Share
1.42
-4.03
-0.78
0.32
0.73
1.91
1.77
1.23
-1.17
2.7
3.89
7.92
6.18
4.73
3.24
- -
0.12
Basic EPS, GAAP
-1.01
-3.39
0.22
0.09
1.51
2.09
-0.77
-0.19
0.58
-0.6
4.24
1.5
-1.38
0.4
2.09
- -
- -
Free Cash Flow per Basic Share
0.3
0.09
0.09
0.09
0.18
0.18
- -
- -
- -
- -
0.17
0.43
0.5
0.5
0.5
- -
- -
Dividend per Share
1
1
1
1
1
1
2.02
3.28
2.14
4.88
8.81
16.31
22
26.2
28.94
- -
1
Book Value per Share
11.35
7.25
6.46
6.67
6.97
12.54
16.63
18.19
17.04
19.76
23.65
31.14
36.8
40.97
43.69
- -
43.15
Tangible Book Value per Share
81
81
81
85
85
85
90
92
92
92
92
92
92
92
92
- -
92
Basic Weighted Avg Shares
2,521
1,577
1,735
1,951
2,019
2,324
2,147
2,086
1,826
2,004
2,293
3,913
3,445
3,766
4,055
3,422
3,422
Sales/Revenue/Turnover
8.55
-13.01
4.55
7.54
8.22
15.2
11.99
8.54
-3.12
13.7
17.85
22.01
16.54
10.42
9.65
-2.9
-2.9
Operating Margin (%)
77
77
89
94
115
119
75
74
80
83
85
95
105
122
99
103
103
Depreciation Expense
114
-325
-63
27
62
163
160
113
-107
248
357
729
569
435
298
11
11
Net Income, GAAP
- -
- -
- -
32.23
- -
11.16
9.13
0.9
- -
7.79
13.62
23.49
21.53
18.56
24.81
40.69
40.69
Effective Tax Rate (%)
4.52
-20.59
-3.64
1.38
3.08
7
7.43
5.41
-5.88
12.36
15.57
18.62
16.52
11.56
7.36
0.33
0.33
Profit Margin (%)
95
-209
35
-27
-21
-297
2
181
32
257
572
1,046
1,254
1,402
1,477
1,388
1,388
Working Capital
609
649
918
768
746
283
124
115
94
121
234
243
284
268
186
219
219
LT Debt
916
585
522
565
592
1,091
1,524
1,688
1,581
1,830
2,185
2,875
3,394
3,777
4,026
3,986
3,986
Total Equity
- -
- -
- -
5.24
- -
16.15
11.14
7.54
- -
9.67
12
19.48
11.03
6.94
6.04
-1.19
-1.19
Return on Invested Capital (%)
- -
- -
- -
8.36
- -
21.79
27.7
22.34
- -
28.42
28.88
39.15
24.08
15.74
10.89
3.26
3.26
Return on Capital (%)
141.62
-403.34
-78.47
32.68
73.44
191.68
119.07
46.65
-43.16
76.84
56.78
63.11
32.28
19.62
11.75
0.83
0.83
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
780
- -
782
LT Borrowings
176
- -
219
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
- -
92
Market Capitalization
12,246
9,281
6,082

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,990
- -
3,050
Cash, Cash Equivalents & STI
190
- -
156
Accounts Receivable, Net
1,734
- -
1,781
Inventories
764
- -
811
Total Current Liabilities
1,739
- -
1,662
Payables & Accruals
- -
- -
- -
ST Debt
780
- -
782
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.58%
13.3%
-1%
Free Cash Flow
-173.36%
-20.63%
-142.19%
Net Income, GAAP
-58.19%
-13.79%
-96.17%
Sales/Revenue/Turnover
6.13%
12.02%
-15.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
966
1,048
825
927
3,766
2025
1,230
1,170
938
717
4,055
2026
976
780
901
765
3,422

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.98
1.23
0.8
- -
4.73
2025
2.68
1.55
0.06
-1.05
3.24
2026
-1.54
-0.39
1.1
0.96
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.5
2026
- -
- -
- -
- -
- -
Similar Companies
Revive Therapeutics Ltd. (RVVTF)
TILT Holdings Inc. (TILT.NE)
Atlas Energy Corp. (CANSF)
The United Laboratories International Holdings Limited (ULIHF)
H. Lundbeck A/S (HLUYY)
Copland Road Capital Corporation (CRCC.CN)
Business
Themis Medicare Limited, a research-based pharmaceutical company (NSE: THEMISMED.BO), manufactures and markets a broad portfolio of differentiated formulations and active pharmaceutical ingredients (APIs) focused on critical therapies including pain management such as Etojet, Aquadol, Joydol, Themidol, and Nimujet; anesthesia products like Ketmin, Themicaine, and Ropicaine; critical care injectables including Dexem and Tazowin; anti-infectives and anti-malarials such as Emal and Lariquin; anti-inflammatories; gynecology and orthopedics offerings like Menogard; cardiology, diabetes, and hypertension medications; antacids; nutritional supplements, vitamins, minerals, and gummies; as well as specialized products in new drug delivery systems (NDDS) encompassing injectables, tablets, capsules, patches, syrups, suspensions, gels, and sprays. Founded in 1969 as a joint venture with Gedeon Richter Ltd., Hungary, and headquartered in Mumbai, India, with manufacturing facilities in Vapi, Gujarat, the company operates three primary plants and serves over 50 countries through domestic marketing, exports, and partnerships emphasizing WHO-GMP, EU-GMP, and PIC/S compliant production. In late 2024, Themis Medicare's board approved a merger with Gujarat Themis Biosyn Limited (established 1981, specializing in fermentation-based APIs), under which it will issue 118 equity shares for every 100 shares of the target pending regulatory approvals to consolidate operations, integrate product value chains, enhance R&D including intermediate molecules and API forward integration, expand fermentation capacity, and strengthen domestic hospital segments in critical care injectables; the company also maintains its renewed partnership with Gedeon Richter, renewed strategic focus on hospital business leadership amid complex injectables expertise, and reported recent board changes in directorate and senior management alongside withdrawal of a prior amalgamation scheme in 2025.